Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Limantrafin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | RAB9A | P51151 | 5/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Limantrafin SCHEMBL30617842 | 1.00 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL25340427 | 0.98 | KDM4E (1.00) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL4638726 | 0.98 | KDM4E (1.00) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL30865022 | 0.97 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| Limantrafin SCHEMBL29221528 | 0.97 | KDM4E (0.97) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL28064235 | 0.89 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL30601045 | 0.89 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL28055507 | 0.89 | KDM4E (0.82) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL31225411 | 0.83 | KDM4E (0.73) | KDM4ERAB9APOLBMEN1KMT2A | |
| SCHEMBL15055437 | 0.83 | KDM4E (0.73) | KDM4ERAB9APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254084-A9 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2024-08-01 | — | — | US | claimed |
| US-20230338347-A1 | New Use of Inhibitors of the Notch Signalling Pathway | CELLESTIA BIOTECH AG (CH) | 2023-10-26 | — | — | US | claimed |
| EP-4213845-A1 | NEW USE OF INHIBITORS OF THE NOTCH SIGNALLING PATHWAY | Cellestia Biotech AG (CH) | 2023-07-26 | — | — | EP | claimed |
| US-20220388961-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2022-12-08 | — | — | US | claimed |
| US-20210323921-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2021-10-21 | — | — | US | claimed |
| CN-112351969-A | Process for preparing aminodiaryl ethers and aminodiaryl ether hydrochlorides | 塞莱斯蒂亚生物技术股份公司 | 2021-02-09 | — | — | CN | claimed |
| US-20240254084-A9 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-12030855-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | CELLESTIA BIOTECH AG (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20230338347-A1 | New Use of Inhibitors of the Notch Signalling Pathway | CELLESTIA BIOTECH AG (CH) | 2023-10-26 | — | — | US | disclosed |
| EP-4213845-A1 | NEW USE OF INHIBITORS OF THE NOTCH SIGNALLING PATHWAY | Cellestia Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20220388961-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11472771-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | CELLESTIA BIOTECH AG (CH) | 2022-10-18 | — | — | US | disclosed |
| US-20210323921-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2021-10-21 | — | — | US | disclosed |
| EP-3810574-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | Cellestia Biotech AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| CN-112351969-A | Process for preparing aminodiaryl ethers and aminodiaryl ether hydrochlorides | 塞莱斯蒂亚生物技术股份公司 | 2021-02-09 | — | — | CN | disclosed |
| WO-2019243523-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254084-A9 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | ADH1C, ADH1A, DDC | KDM4E 499/4885RAB9A 932/4885POLB 2056/4885 |
| US-11472771-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | ADH1C, ADH1A, DDC | KDM4E 499/4885RAB9A 932/4885POLB 2056/4885 |
| US-20210323921-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | ADH1C, ADH1A, DDC | KDM4E 499/4885RAB9A 932/4885POLB 2056/4885 |
| US-20230338347-A1 | New Use of Inhibitors of the Notch Signalling Pathway | NOTCH1, NOTCH2, NOTCH4 | KDM4E 892/4885RAB9A 3556/4885POLB 3352/4885 |
| US-20220388961-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | ADH1C, ADH1A, DDC | KDM4E 499/4885RAB9A 932/4885POLB 2056/4885 |
| US-12030855-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | ADH1C, ADH1A, DDC | KDM4E 499/4885RAB9A 932/4885POLB 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.